We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cadila Healthcare announced it has received approval from the FDA to market its generic version of GlaxoSmithKline's (GSK) Paxil in strengths of 10, 20, 30 and 40 mg.
IDM Pharma recently announced the completion of patient enrollment in two Phase II clinical trials of Uvidem, IDM's therapeutic product for the treatment of melanoma being developed in collaboration with sanofi-aventis.
Panacos Pharmaceuticals announced it has agreed with the FDA on a revised trial design for the company's Phase IIb clinical study of bevirimat (PA-457), the first-in-class maturation inhibitor for the treatment of HIV infection.
Spectrum Pharmaceuticals announced it has reached an agreement with the FDA under the special protocol assessment (SPA) procedure for the company's bladder cancer drug candidate, EOquin.
La Jolla Pharmaceutical has announced positive interim results from its ongoing double-blind, placebo-controlled, randomized, Phase III trial of Riquent, the company's drug candidate for systemic lupus erythematosus.